InduPro raised $85 million in a Series A financing co-led by The Column Group and Vida Ventures to advance next-generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Disease.
InduPro raised $85 million in a Series A financing co-led by The Column Group and Vida Ventures to advance next-generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Disease.
06/13/24, 7:22 PM
Location
seattleMoney raised
$85 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Euclidean Capital, Emerson Collective, Mrl Ventures Fund, Vida Ventures, The Column Group
InduPro, a biotechnology company, announced an $85 million Series A financing co-led by The Column Group and Vida Ventures with participation from investors, including MRL Ventures Fund, Emerson Collective, and Euclidean Capital. The funding will support the advancement of the first expected clinical product candidate targeting cancer tissue based on the proximity of co-targeted pairs and fuel a pipeline of novel bispecific antibodies and antibody drug conjugates.
Company Info
Location
seattle, washington, united states
Additional Info
InduPro, Inc. is a biotechnology company that defines protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases. They target cell surface proteins in a variety of disease contexts by leveraging inherent or induced protein proximity. Their approach relies on a unique discovery engine (ProXiMATE) to generate potential first-in-class and best-in-class novel therapeutic candidates across multiple indications and modalities.